'use strict';
/*
 * Article source. Body HTML in `sections[].html` is scanned by the compliance
 * gate — keep it research-use-only: no human dosing, no therapeutic/outcome
 * claims. Compliance boilerplate (RUO callout, disclaimer) is added by the
 * template automatically and is exempt from the scan.
 */
module.exports = {
  slug: 'retatrutide-vs-tirzepatide',
  metaTitle: 'Retatrutide vs Tirzepatide | Research Compound Comparison',
  title: 'Retatrutide vs Tirzepatide: Research Compound Comparison',
  htmlTitle: 'Retatrutide vs Tirzepatide<br><em>Research Compound Comparison</em>',
  description: 'Retatrutide vs Tirzepatide compared as research compounds — receptor targets, supplied form, purity, handling and UK availability. Research use only.',
  keyword: 'retatrutide vs tirzepatide',
  category: 'Compound Comparison',
  datePublished: '2026-06-26',
  dateModified: '2026-06-26',
  cardSummary: 'How two of the most-requested metabolic research compounds compare on receptor targets, supplied form, purity and UK handling.',
  intro: 'Retatrutide and Tirzepatide are two of the most frequently requested metabolic research compounds in the UK. They belong to the same broad class of receptor-agonist peptides but differ in their molecular targets, the vial sizes they are supplied in, and how researchers select between them for a given model. This guide compares them strictly as laboratory research materials.',
  relatedProducts: ['retatrutide', 'tirzepatide', 'bacteriostatic-water', 'syringe-kit'],

  sections: [
    {
      id: 'at-a-glance',
      heading: 'Retatrutide and Tirzepatide at a Glance',
      html: `      <p>Both compounds are supplied by North Peptides UK as lyophilised (freeze-dried) powder in sealed vials, verified to 99%+ purity and stored frozen until dispatch. The table below summarises how they compare as research materials before we look at each attribute in detail.</p>
      <table class="compare-table">
        <thead>
          <tr><th>Attribute</th><th>Retatrutide</th><th>Tirzepatide</th></tr>
        </thead>
        <tbody>
          <tr><td>Compound class</td><td>Triple receptor agonist</td><td>Dual receptor agonist</td></tr>
          <tr><td>Receptor targets</td><td>GLP-1, GIP and glucagon receptors</td><td>GIP and GLP-1 receptors</td></tr>
          <tr><td>Supplied as</td><td>Lyophilised vial</td><td>Lyophilised vial</td></tr>
          <tr><td>Vial sizes (UK)</td><td>10mg, 15mg, 20mg</td><td>15mg, 30mg</td></tr>
          <tr><td>Verified purity</td><td>99%+</td><td>99%+</td></tr>
          <tr><td>Reconstitution solvent</td><td>Bacteriostatic water</td><td>Bacteriostatic water</td></tr>
          <tr><td>UK availability</td><td>Stocked, 24h dispatch</td><td>Stocked, 24h dispatch</td></tr>
        </tbody>
      </table>`,
    },
    {
      id: 'receptor-targets',
      heading: 'The Core Difference: Receptor Targets',
      html: `      <p>The defining difference between the two compounds is the set of receptors they act on. This is what researchers are usually comparing when they weigh one against the other.</p>
      <p><strong>Tirzepatide</strong> is a dual agonist. As a single molecule it engages both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. It is widely used as a reference compound in metabolic receptor-signalling research because it combines two incretin pathways in one sequence.</p>
      <p><strong>Retatrutide</strong> extends this profile to three receptors. In addition to GLP-1 and GIP, it also acts on the glucagon receptor, which is why it is described as a triple agonist or "tri-agonist". For a research model designed to probe glucagon-receptor involvement alongside the two incretin pathways, Retatrutide is the compound that covers all three targets in a single molecule.</p>
      <p>In short: if a study is concerned only with the GIP and GLP-1 pathways, Tirzepatide is the more targeted choice. If the glucagon receptor is also part of the experimental question, Retatrutide adds that third pathway.</p>`,
    },
    {
      id: 'supplied-form',
      heading: 'How Each Is Supplied',
      html: `      <p>Both are supplied as lyophilised powder, the most stable format for transport and storage. North Peptides UK stocks the following vial sizes:</p>
      <ul>
        <li><strong><a href="/product.html?product=retatrutide">Retatrutide</a></strong> — 10mg, 15mg and 20mg vials, from £45. Verified to 99%+ purity with a certificate of analysis available on request.</li>
        <li><strong><a href="/product.html?product=tirzepatide">Tirzepatide</a></strong> — 15mg and 30mg vials, from £65. Verified to 99%+ purity with a certificate of analysis available on request.</li>
      </ul>
      <p>Each batch is stored frozen until dispatch and shipped from the UK with tracked delivery, typically within 24 hours on business days. The larger vial sizes are usually selected where a research protocol calls for a higher total quantity of material per vial.</p>`,
    },
    {
      id: 'handling-reconstitution',
      heading: 'Handling and Reconstitution',
      html: `      <p>Both compounds are handled in the same way in the laboratory. As lyophilised powders they are reconstituted with <a href="/product.html?product=bacteriostatic-water">bacteriostatic water</a> before use in a research preparation. Both dissolve readily; a 2ml to 4ml volume of solvent per vial is a common working dilution when preparing material for laboratory use.</p>
      <p>The handling principles are identical to any peptide of this class: direct the solvent down the inside wall of the vial rather than onto the powder, swirl gently rather than shake, and label the vial with the preparation date. Our <a href="/blog/how-to-reconstitute-peptides.html">reconstitution guide</a> covers the full procedure and the concentration arithmetic for each vial size.</p>
      <div class="callout callout-green">
        <div class="callout-title">Same Consumables for Both</div>
        <p>Because both compounds reconstitute identically, the same preparation supplies cover either one: bacteriostatic water as the solvent, sterile needles for transfer, and alcohol wipes for cleaning vial tops. A single consumables order serves a workflow using either compound.</p>
      </div>`,
    },
    {
      id: 'stability-storage',
      heading: 'Stability and Storage',
      html: `      <p>In lyophilised form, both compounds are stable and are kept frozen for longer-term storage. The difference in handling appears only after reconstitution:</p>
      <ul>
        <li><strong>Before reconstitution</strong> — keep the sealed vial frozen and away from light. The freeze-dried powder is the most stable state and tolerates transport at room temperature for short periods.</li>
        <li><strong>After reconstitution</strong> — refrigerate the prepared solution at 2–8°C, keep it out of direct light, and avoid repeated freeze–thaw cycles, which place mechanical stress on the molecule.</li>
      </ul>
      <p>Neither compound is more fragile than the other in this respect; they follow the same stability rules as the wider peptide class.</p>`,
    },
    {
      id: 'choosing',
      heading: 'Choosing Between Them for a Research Model',
      html: `      <p>The decision usually comes down to the experimental question rather than any difference in handling or quality, since both are supplied at the same verified purity. A few considerations researchers commonly weigh:</p>
      <ul>
        <li><strong>Pathway coverage</strong> — Tirzepatide isolates the GIP and GLP-1 pathways; Retatrutide adds glucagon-receptor activity. The model's design dictates which is appropriate.</li>
        <li><strong>Reference comparability</strong> — Tirzepatide has a longer track record as a dual-agonist reference compound, which can matter when a study is being compared against existing literature.</li>
        <li><strong>Quantity per vial</strong> — available vial sizes differ (10–20mg for Retatrutide, 15–30mg for Tirzepatide), which affects how many preparations a single vial yields.</li>
        <li><strong>Availability</strong> — both are UK stocked with 24-hour dispatch, so lead time is not usually a differentiator.</li>
      </ul>
      <p>Some research programmes hold both on hand precisely so the same protocol can be run across the dual- and triple-agonist profiles for comparison.</p>`,
    },
    {
      id: 'sourcing-uk',
      heading: 'Sourcing Both in the UK',
      html: `      <p>North Peptides UK stocks both compounds domestically, so there are no import delays or customs handling for UK-based researchers. Every batch is verified to 99%+ purity, stored frozen until dispatch, and accompanied by a certificate of analysis on request.</p>
      <p>Orders are dispatched within 24 hours on business days with tracked delivery. If you need help confirming vial sizes or purity documentation before ordering, you can reach the team directly on Telegram at ${'@NORTHPEPTIDESUK'}.</p>`,
    },
  ],

  faqs: [
    { q: 'What is the main difference between Retatrutide and Tirzepatide?',
      a: 'Their receptor targets. Tirzepatide is a dual agonist acting on the GIP and GLP-1 receptors, while Retatrutide is a triple agonist that also acts on the glucagon receptor. Both are supplied as lyophilised research compounds.' },
    { q: 'Are Retatrutide and Tirzepatide available in the UK?',
      a: 'Yes. Both are UK stocked by North Peptides UK and dispatched within 24 hours on business days, verified to 99%+ purity with a certificate of analysis available on request.' },
    { q: 'How are these research compounds supplied?',
      a: 'As lyophilised (freeze-dried) powder in sealed vials, stored frozen until dispatch. Retatrutide is stocked in 10mg, 15mg and 20mg vials; Tirzepatide in 15mg and 30mg vials.' },
    { q: 'Can these research compounds be used in humans?',
      a: 'No. Both are supplied strictly for laboratory and scientific research and are not for human or animal consumption.' },
  ],
};
